

Table 4 Reasons for choosing a second-line therapy in the study sample: 348 patients aged \geq 18 years with T2DM who were starting second-line glucose-lowering therapy, Lebanon, 2015-2019

Reason	No. (%) of patients
Efficacy	273 (78.4)
Tolerability	85 (24.4)
Hypoglycaemia	84 (24.1)
Weight gain	66 (19.0)
Patient convenience/comfort	30 (8.6)
Cost	24 (6.9)
Patient request	12 (3.4)
Access reason	11 (3.2)
Other	22 (6.9)